BiotechTube

EXS21546

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumours

Conditions

Advanced Solid Tumours

Trial Timeline

Apr 11, 2023 → Oct 23, 2023

NCT ID
NCT05920408

About EXS21546

EXS21546 is a phase 1/2 stage product being developed by Biotrial for Advanced Solid Tumours. The current trial status is terminated. This product is registered under clinical trial identifier NCT05920408. Target conditions include Advanced Solid Tumours.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05920408Phase 1/2Terminated

Competing Products

20 competing products in Advanced Solid Tumours

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25
LY3200882 + PembrolizumabEli LillyPhase 1/2
41

Other Products from Biotrial

Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)Phase 1/2
33
LPH-5 + PlaceboPhase 1
25
Binimetinib Oral TabletPhase 1
25
ITF2357Phase 1
25
VNA-318 + PlaceboPhase 1
25